JP2019526584A - 脊髄損傷の治療のための多能性幹細胞由来オリゴデンドロサイト前駆細胞 - Google Patents

脊髄損傷の治療のための多能性幹細胞由来オリゴデンドロサイト前駆細胞 Download PDF

Info

Publication number
JP2019526584A
JP2019526584A JP2019512280A JP2019512280A JP2019526584A JP 2019526584 A JP2019526584 A JP 2019526584A JP 2019512280 A JP2019512280 A JP 2019512280A JP 2019512280 A JP2019512280 A JP 2019512280A JP 2019526584 A JP2019526584 A JP 2019526584A
Authority
JP
Japan
Prior art keywords
cells
subject
spinal cord
cord injury
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019512280A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526584A5 (enExample
Inventor
ヴィルト，エドワード，ディー．，サード
エス． レブコフスキー，ジェーン
エス． レブコフスキー，ジェーン
Original Assignee
アステリアス バイオセラピューティクス インコーポレイテッド
アステリアス バイオセラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アステリアス バイオセラピューティクス インコーポレイテッド, アステリアス バイオセラピューティクス インコーポレイテッド filed Critical アステリアス バイオセラピューティクス インコーポレイテッド
Publication of JP2019526584A publication Critical patent/JP2019526584A/ja
Publication of JP2019526584A5 publication Critical patent/JP2019526584A5/ja
Priority to JP2022096318A priority Critical patent/JP2022130483A/ja
Priority to JP2024061113A priority patent/JP2024096794A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019512280A 2016-09-14 2017-09-14 脊髄損傷の治療のための多能性幹細胞由来オリゴデンドロサイト前駆細胞 Pending JP2019526584A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022096318A JP2022130483A (ja) 2016-09-14 2022-06-15 脊髄損傷の治療のための多能性幹細胞由来オリゴデンドロサイト前駆細胞
JP2024061113A JP2024096794A (ja) 2016-09-14 2024-04-04 脊髄損傷の治療のための多能性幹細胞由来オリゴデンドロサイト前駆細胞

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662394226P 2016-09-14 2016-09-14
US62/394,226 2016-09-14
US201762449580P 2017-01-23 2017-01-23
US62/449,580 2017-01-23
US201762518591P 2017-06-12 2017-06-12
US62/518,591 2017-06-12
PCT/US2017/051677 WO2018053210A1 (en) 2016-09-14 2017-09-14 Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022096318A Division JP2022130483A (ja) 2016-09-14 2022-06-15 脊髄損傷の治療のための多能性幹細胞由来オリゴデンドロサイト前駆細胞

Publications (2)

Publication Number Publication Date
JP2019526584A true JP2019526584A (ja) 2019-09-19
JP2019526584A5 JP2019526584A5 (enExample) 2020-11-12

Family

ID=61620153

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019512280A Pending JP2019526584A (ja) 2016-09-14 2017-09-14 脊髄損傷の治療のための多能性幹細胞由来オリゴデンドロサイト前駆細胞
JP2022096318A Pending JP2022130483A (ja) 2016-09-14 2022-06-15 脊髄損傷の治療のための多能性幹細胞由来オリゴデンドロサイト前駆細胞
JP2024061113A Pending JP2024096794A (ja) 2016-09-14 2024-04-04 脊髄損傷の治療のための多能性幹細胞由来オリゴデンドロサイト前駆細胞

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022096318A Pending JP2022130483A (ja) 2016-09-14 2022-06-15 脊髄損傷の治療のための多能性幹細胞由来オリゴデンドロサイト前駆細胞
JP2024061113A Pending JP2024096794A (ja) 2016-09-14 2024-04-04 脊髄損傷の治療のための多能性幹細胞由来オリゴデンドロサイト前駆細胞

Country Status (7)

Country Link
US (1) US20190262405A1 (enExample)
EP (1) EP3518945A4 (enExample)
JP (3) JP2019526584A (enExample)
CN (1) CN109715175A (enExample)
AU (1) AU2017326424B2 (enExample)
CA (1) CA3036832A1 (enExample)
WO (1) WO2018053210A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023531358A (ja) * 2020-05-01 2023-07-24 ザ チルドレンズ メディカル センター コーポレーション ミエリン形成を促進する組成物および方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12365872B2 (en) 2018-09-19 2025-07-22 Lineage Cell Therapeutics, Inc. Methods for differentiating pluripotent stem cells in dynamic suspension culture
EP4284397A4 (en) * 2021-01-28 2025-04-16 Asterias Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING SPINAL CORD INJURIES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7285415B2 (en) * 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
AR046076A1 (es) * 2003-07-18 2005-11-23 Otsuka Pharma Co Ltd Procedimiento para obtener una poblacion homogenea de celulas precursoras de oligodendrocitos y poblacion obtenida

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV., vol. NCT02302157 on 2016_05_18, JPN6021032083, May 2016 (2016-05-01), ISSN: 0004706016 *
KENNEDY INSTITUTE OF ETHICS JOURNAL, vol. 22(3), JPN6021032086, 2012, pages 243 - 261, ISSN: 0004572377 *
STEM CELLS, vol. 28, JPN6021032080, 2010, pages 152 - 163, ISSN: 0004706015 *
THE JOURNAL OF NEUROSCIENCE, vol. 25(19), JPN6021032078, 2005, pages 4694 - 4705, ISSN: 0004706014 *
実験医学, vol. 28(5), JPN6022005828, 2010, pages 830 - 835, ISSN: 0004706017 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023531358A (ja) * 2020-05-01 2023-07-24 ザ チルドレンズ メディカル センター コーポレーション ミエリン形成を促進する組成物および方法

Also Published As

Publication number Publication date
AU2017326424A1 (en) 2019-04-18
US20190262405A1 (en) 2019-08-29
EP3518945A4 (en) 2020-04-22
CA3036832A1 (en) 2018-03-22
WO2018053210A1 (en) 2018-03-22
JP2022130483A (ja) 2022-09-06
CN109715175A (zh) 2019-05-03
JP2024096794A (ja) 2024-07-17
AU2017326424B2 (en) 2023-12-14
EP3518945A1 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
JP5649786B2 (ja) ヒト胚性幹細胞およびそれらの誘導体を含む組成物、使用方法、ならびに調製方法
US9387226B2 (en) Neural cell proliferation induced through the culture of neural cells with umbilical cord blood-derived mesenchymal stem cells
JP2024096794A (ja) 脊髄損傷の治療のための多能性幹細胞由来オリゴデンドロサイト前駆細胞
CN111566204B (zh) 培养细胞的制造方法、脊髓损伤疾病的治疗剂的制造方法
JP7313133B2 (ja) 脳卒中のための神経幹細胞治療
ES2748475T3 (es) Composiciones que comprenden células madre embrionarias humanas y sus derivados, procedimientos de uso y procedimientos de preparación

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200911

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220215